1 BTC
=
- USD
Aerovate Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Aerovate Therapeutics, Inc. Common Stock
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Market Statistics
Trading Metrics
How to Buy AVTE
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy AVTE
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesJade Biosciences, a biotechnology company focused on autoimmune diseases, has completed its merger with Aerovate Therapeutics and raised $300 million in a private placement. The combined company will advance its lead candidate JADE-001 for IgA nephropathy, with plans to enter the clinic in the second half of 2025.
Aerovate Therapeutics announced a special cash dividend of $69.6 million, or an estimated $2.40 per share, in connection with its proposed merger with Jade Biosciences. The dividend is contingent on the closing of the merger, which is expected to occur on or about April 28, 2025.
Monteverde & Associates PC, a top 50 securities class action firm, is investigating several proposed mergers, including Amplify Energy Corp., H&E Equipment Services, Aerovate Therapeutics, and Triumph Group. The firm is encouraging shareholders to act now as shareholder votes are scheduled in April 2025.
